Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Similar articles for PubMed (Select 17760991)

1.
2.
3.

Goal setting and attainment in Alzheimer's disease patients treated with donepezil.

Rockwood K, Graham JE, Fay S; ACADIE Investigators.

J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):500-7.

4.

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.

Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44.

PMID:
10325453
5.

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators.

CMAJ. 2006 Apr 11;174(8):1099-105. Epub 2006 Mar 22.

6.

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey R.

Cochrane Database Syst Rev. 2003;(3):CD001190. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001190.

PMID:
12917900
7.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
8.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
9.

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.

Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M.

Eur J Neurol. 2010 Mar;17(3):405-12. doi: 10.1111/j.1468-1331.2009.02816.x. Epub 2009 Oct 28.

PMID:
19874395
10.

Verbal repetition in patients with Alzheimer's disease who receive donepezil.

Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, Dei DW, Rockwood K.

Int J Geriatr Psychiatry. 2006 May;21(5):426-31.

PMID:
16676290
11.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
12.

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

Matthews HP, Korbey J, Wilkinson DG, Rowden J.

Int J Geriatr Psychiatry. 2000 Aug;15(8):713-20.

PMID:
10960883
13.

The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E.

J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

PMID:
22959283
14.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
15.

Two galantamine titration regimens in patients switched from donepezil.

Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.

Acta Neurol Scand. 2012 Jul;126(1):37-44. doi: 10.1111/j.1600-0404.2011.01594.x. Epub 2011 Oct 13.

PMID:
21992111
16.

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.

Burns A, Gauthier S, Perdomo C.

Int J Geriatr Psychiatry. 2007 Aug;22(8):806-12.

PMID:
17199235
17.

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.

Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R.

Int J Geriatr Psychiatry. 2004 Jan;19(1):58-67.

PMID:
14716700
18.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
19.

A naturalistic study of galantamine for Alzheimer's disease.

Brodaty H, Woodward M, Boundy K, Barnes N, Allen G; NATURE Investigators.

CNS Drugs. 2006;20(11):935-43.

PMID:
17044730
20.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk